Zoetis Inc. (NYSE:ZTS) Shares Purchased by DAVENPORT & Co LLC

DAVENPORT & Co LLC increased its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 1.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 48,139 shares of the company’s stock after acquiring an additional 812 shares during the quarter. DAVENPORT & Co LLC’s holdings in Zoetis were worth $9,501,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Evermay Wealth Management LLC grew its holdings in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at approximately $26,000. VisionPoint Advisory Group LLC acquired a new position in shares of Zoetis in the 2nd quarter worth approximately $29,000. Finally, Moisand Fitzgerald Tamayo LLC boosted its position in shares of Zoetis by 105.5% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS stock opened at $162.94 on Thursday. The business has a 50 day moving average price of $184.16 and a 200 day moving average price of $181.77. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock has a market cap of $74.52 billion, a price-to-earnings ratio of 32.14, a PEG ratio of 2.52 and a beta of 0.85. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.15 EPS. Equities research analysts anticipate that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Analyst Ratings Changes

A number of research analysts have commented on the company. The Goldman Sachs Group upped their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler lifted their target price on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th. Jefferies Financial Group reissued a “buy” rating and set a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, BNP Paribas initiated coverage on Zoetis in a report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 target price for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $222.11.

View Our Latest Stock Report on Zoetis

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.12% of the company’s stock.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.